Transcatheter is a minimally invasive
procedure, used to change the valve in patients with cardiac stenosis without
eliminating a damaged or old valve. It is frequently used to replace the
damaged heart valve. It has drastically altered an outlook of treatment with
minimally invasive procedures in approximately all therapeutic areas. Some of
the side-effects are included bleeding, problems with the replacement valve,
for instance the valve slipping out of place or leaking, blood vessel
complications, heart rhythm abnormalities (arrhythmias), stroke, heart attack,
kidney disease and infection etc.
According to study, “Global
Transcatheter Market Research Report: By Type of Treatment
(Transfemoral Approach, Transapical Approach, and Others), by Product Type
(TAVR and TMVR), by End-User (Hospitals, Ambulatory Surgical Centers, Others),
and by Region-Forecast Till 2023” the key companies operating in the global
transcatheter market are Edward Lifesciences Corporation, Braile Biomedica,
Meril Life Sciences Pvt. Ltd, Venus Medtech Inc., JenaValve Technology, Inc.,
Direct Flow Medical Inc., Boston Scientific Corporation, Symetis SA, Abbott
Laboratories Inc., Bracco Diagnostic Inc. (HLT, Inc.), Medtronic Plc., NVT AG,
St. Jude Medical Inc., JC Medical Inc., Cook Medical Inc.
Based on valve type, transcatheter market is
segmented into Transcatheter Pulmonary Valve Replacement (TPVR) and
Transcatheter Aortic Valve Replacement (TAVR). TAVR segment dominate the market
owing to high acceptance of TAVR over TMVR as it contains of repairing the
valve without an extraction of the old damaged valve. Based on type of
treatment, market is segmented into transapical approach, transfemoral approach
and others (transaortic approach). The transfemoral approach holds major share
due to rise in prevalence of valvular heart diseases in older adult population,
and growth in advancements in transcatheter heart valves. The transaortic
approach segment is anticipated to grow at the highest CAGR during the forecast
period as a result of rise in aorta cannulation which is routine in cardiac
surgeries. In addition, based on end-user, market is segmented into ambulatory
surgical centers, hospitals, cardiac catheterization laboratory and others.
Hospitals are the leading users of transcatheters as a result of the high
number of patients admitted for different treatment procedures.
The transcatheter market is driven by rise in
incidence of valvular heart diseases, followed by favourable reimbursement
scenario, increase in per capita income, growth in adoption of minimally
invasive procedures, rise in healthcare expenditures, rise in prevalence of
cardiovascular diseases, and increase in number of TAVR procedure. However,
rise in associated risks with TAVR and varied stringency of regulatory
procedures delays product launches may impact the market. Moreover, expansion
of TAVR to low & intermediate risk patients and rise in focus on
transcatheter mitral valve replacement are key opportunities for market.
Based on geography, the Asian-Pacific region
holds major share, followed by European region in transcatheter market owing to
rise in geriatric population, increase in surgical procedure volumes and growth
in number of endovascular procedures in the region. The North-American region
is expected to witness higher growth rate due to launch of technologically
advanced & innovative products over the forecast period. It is estimated
that future of the market will be bright on account of introduction of
innovative products for instance transcatheter mitral valve repair devices,
chronic total occlusion devices, and aortic stents during the forecast period.
It is projected that the market will be reached at US $8,191.26 million, at a
CAGR of 13.38%, by 2023.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91
9015378249